Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Bamlanivimab/etesevimab may leads to lower admission to hospital or death compared with placebo (low certainty).
1 finding from 1 review
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower admission to hospital or death by day 30 compared with placebo (low certainty).
1 finding from 1 review
Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Regdanvimab showed no clear difference in admission to hospital or death by day 30Â compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Admission to hospital or death up to day 45 · non‐hospitalised adults with mild COVID‐19
It is very uncertain whether the intervention changes admission to hospital or death up to day 45 (very low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard care alone (low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · outpatients withmild disease
Summary of findings table ‐ Convalescent plasma probably leads to lower admission to hospital or death within 28 days compared with standard plasma (moderate certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in admission to hospital or death within 28 days compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Admission to hospital or death within 28 days · people with SARS‐CoV‐2 infection and asymptomatic or mild disease
1 finding from 1 review
All‐cause admission to hospital or death (before hospital admission) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause admission to hospital or death (before hospital admission) compared with placebo plus standard care (low certainty).
1 finding from 1 review
Intervention not reported
Worsening of clinical status: admission to hospital or death within 28 days · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in worsening of clinical status: admission to hospital or death within… (low certainty).
1 finding from 1 review